Objective: The need for a standardised instrument to measure the impact of glucocorticoid (GC) therapy has been well documented in the literature. The aim of the first GC SIG was to define a research agenda around the development of a patient reported outcome measure (PRO) in this area.
Introduction
Glucocorticoids (GCs) have had a prominent role in the treatment of inflammatory diseases for over 60 years, with 0.5-1% of adults considered current long-term users(1-3). They are effective anti-inflammatory agents, however they have many known associated adverse effects (AEs). While GC-AEs have been well documented (4) (5) (6) (7) (8) , the absolute risk of many GC-AEs has not been quantified (5, 9) . This may be because AEs are poorly captured in RCTs, or may reflect differences in AEs when GCs are prescribed for different indications and doses (10) (11) (12) (13) (14) . A EULAR taskforce on GC therapy has published two systematic reviews concluding that there is a need to systematically capture GC-AEs in a standardised manner (10, 12) . In 
Main findings
A literature search revealed a PRO that measures the effects of inhaled GCs, but no PRO for the effects of systemic GCs was found. The preliminary results of a pilot survey and two qualitative studies demonstrated that patients report outcomes including sleep disturbance, weight gain, and skin fragility that are not typically measured by clinicians. These data facilitated discussion regarding the need for a PRO for the impact of GCs.
What is novel?
The GC SIG met for the first time at OMERACT 2016 and all data presented was new.
In addition, the first OMERACT research agenda in this area was defined, with a focus on the need to further understand the impact of GCs amongst patients of different ages and with different diagnoses and GC exposure. The aim of this research agenda is to identify relevant domains.
WHAT IS NEW?
 No patient reported outcome measure for assessing the impact of systemic 
How this advances published research to date
The findings presented confirm the need for a standardized instrument to measure the unrecognized impact of GCs from the patient perspective.
The work presented in this paper has not previously been published elsewhere. Figure S1) . The ICQ contains 57 items across 15
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Glucocorticoid Adverse Effects
categories; 38 items capture inhalation related AEs affecting the oropharynx, taste and voice and 19 items are related to systemic AEs of inhaled GCs including mood, skin/hair/nails, perspiration and tiredness amongst others (Figure 1 ).
Glucocorticoid Adverse Effects Reported in Randomised Controlled Trials of Inflammatory Disorders
An exploratory exercise to determine which GC-AEs have been reported in RCTs was carried out using the studies reported in SLRs of PMR (9 RCTs), C D 
Glucocorticoid Adverse Effects-The Patient Perspective (Pilot Survey)
A cross-sectional pilot survey was performed to determine GC-AEs from the patient perspective. Participants attended an Australian tertiary rheumatology clinic (n=55) and were currently taking oral prednisone or had taken it within the past 12 months.
The survey included a checklist of known AEs and participants were asked were the worst side effects you had? . Participants were also asked to indicate GC AE they experienced were worse than the benefits of treatment (Yes/No/Not sure). 
A qualitative assessment of GC use in ANCA associated vasculitis
The OMERACT vasculitis working group are key collaborators in the international 
Summary of the OMERACT 2016 Glucocorticoid SIG
Participants in the inaugural GC SIG agreed on the need for a data driven PRO that captures both positive and negative effects of GC use, to be used across all inflammatory indications for systemic GC use in adults. The participants recognized the difficulty of determining how this might fit within the OMERACT framework, as the Filter 2.0 (23) has not been designed to address AEs as an outcome; however, it was felt that the framework would nonetheless be helpful.
A research agenda was developed for development of a GC impact PRO:
1. To conduct further qualitative work in populations with different GC indications to identify relevant domains.
2. To address differences in age groups (adults), GC dose and duration of use.
3. To define and quantify the value patients place on GC benefits and harms and determine differences from physicians.
4. To explore the sense of conflict patients describe when physicians recommend tapering, while they feel they need ongoing GC therapy.
In addition, it was agreed that this group would benefit from engagement and collaboration with the OMERACT Drug Safety Group.
Conclusion
When assessing novel therapies for inflammatory conditions treated with GCs, it is important to capture the relevant GC-related risks and benefits. Based on the background evidence presented, attendees agreed that a PRO instrument should be developed. A research agenda has been established to broaden our understanding of the positive and negative impacts of GCs across different indications, ages and doses. The group will be well placed to develop a preliminary core outcome set at OMERACT 2018. 
